



Roche Group Early-stage Development Pipeline

PHASE I (35 NMEs)			PHASE II (21 NMEs)		
<p>ONCOLOGY (15 NMEs)</p> <p>3rd Gen. Anti-CD20/GA101 (RG7159)</p> <ul style="list-style-type: none"> Hematologic malignancies <p>ABT-263 (RG7433)</p> <ul style="list-style-type: none"> Solid tumors and hematologic malignancies <p>Anti-EGFL7 (RG7414)</p> <ul style="list-style-type: none"> Solid tumors <p>Anti-NRP1 (RG7347)</p> <ul style="list-style-type: none"> Solid tumors <p>Anti-PLGF (RG7334)</p> <ul style="list-style-type: none"> Solid tumors <p>CKI27 (RG7304)</p> <ul style="list-style-type: none"> Solid tumors <p>Dacetuzumab (RG3636)</p> <ul style="list-style-type: none"> Diffuse large B-cell lymphoma Multiple myeloma Non-Hodgkin's lymphoma (NHL) <p>DR5 Agonist MAb (RG7425)</p> <ul style="list-style-type: none"> Colorectal cancer <p>Dulanermin (RG3639)</p> <ul style="list-style-type: none"> Colorectal cancer <p>G-secretase Inh (RG4733)</p> <ul style="list-style-type: none"> Solid tumors <p>huMAb EGFR/GA201 (RG7160)</p> <ul style="list-style-type: none"> Solid tumors <p>huMAb Glypican-3/GC33¹</p> <ul style="list-style-type: none"> Hepatocellular (liver) carcinoma <p>IAP Antagonist (RG7419)</p> <ul style="list-style-type: none"> Solid tumors <p>MDM2 Antagonist (RG7112)</p> <ul style="list-style-type: none"> Solid tumors and hematologic malignancies <p>MEK Inh/CIF (RG7167)</p> <ul style="list-style-type: none"> Solid tumors <p>MEK Inh/GDC-0973 (RG7420)</p> <ul style="list-style-type: none"> Solid tumors <p>MetMAb (RG3638)</p> <ul style="list-style-type: none"> Solid tumors 	<p>PI3 Kinase Inh/GDC-0941 (RG7321)</p> <ul style="list-style-type: none"> Metastatic breast cancer Metastatic NSCLC <p>PI3 Kinase Inh/GDC-0980 (RG7422)</p> <ul style="list-style-type: none"> Solid tumors and NHL <p>Topoisomerase I Inh/TP300¹</p> <ul style="list-style-type: none"> Colorectal cancer <p>INFLAMMATION (7 NMEs)</p> <p>Anti-CD4 (RG7424)</p> <ul style="list-style-type: none"> Rheumatoid arthritis <p>Anti-LT α (RG7416)</p> <ul style="list-style-type: none"> Rheumatoid arthritis <p>huMAb OX40L (RG4930)</p> <ul style="list-style-type: none"> Asthma <p>P2X3 Antagonist (RG1646)</p> <ul style="list-style-type: none"> Pain <p>rhuMAb-β7 (RG7413)</p> <ul style="list-style-type: none"> Ulcerative colitis <p>VAP-1 Antibody²</p> <ul style="list-style-type: none"> Rheumatoid arthritis Plaque psoriasis <p>VPAC2 Agonist (RG7103)</p> <ul style="list-style-type: none"> Chronic obstructive pulmonary disease <p>VIROLOGY (1 NME)</p> <p>Serine Palmitoyltransferase Inh/NA808⁴</p> <ul style="list-style-type: none"> Chronic hepatitis C <p>Protease Inh + ritonavir (RG7227)</p> <ul style="list-style-type: none"> Chronic hepatitis C <p>Protease Inh (RG7227) + Nucleoside Analogue Polymerase Inh (RG7128)</p> <ul style="list-style-type: none"> Chronic hepatitis C 	<p>METABOLIC (7 NMEs)</p> <p>11 Beta HSD Inh (RG4929)</p> <ul style="list-style-type: none"> Type II diabetes <p>11 Beta HSD Inh (RG7234)</p> <ul style="list-style-type: none"> Type II diabetes <p>Anti-oxLDL (RG7418)</p> <ul style="list-style-type: none"> Secondary prevention of cardiovascular events <p>BHT-3021 (RG7426)</p> <ul style="list-style-type: none"> Type I diabetes <p>C-Raf Inh/PLX5568 (RG7376)</p> <ul style="list-style-type: none"> Polycystic kidney disease <p>P-selectin huMAb (RG1512)</p> <ul style="list-style-type: none"> Peripheral vascular disease <p>Y2R Agonist Peptide (RG7089)</p> <ul style="list-style-type: none"> Type II diabetes <p>CNS (4 NMEs)</p> <p>Anti-Aβ (RG7412)</p> <ul style="list-style-type: none"> Alzheimer's disease <p>Gantenerumab/Anti-Aβ (RG1450)</p> <ul style="list-style-type: none"> Alzheimer's disease <p>PEG IGF-1 (RG7010)</p> <ul style="list-style-type: none"> Neurodegeneration amyotrophic lateral sclerosis <p>mGluR2 Antagonist (RG1578)</p> <ul style="list-style-type: none"> Depression <p>OPHTHALMOLOGY (1 NME)</p> <p>Anti-Factor D (RG7417)</p> <ul style="list-style-type: none"> Geographic atrophy associated with age-related macular degeneration 	<p>ONCOLOGY (9 NMEs)</p> <p>3rd Gen. Anti-CD20/GA101 (RG7159)</p> <ul style="list-style-type: none"> Indolent NHL Relapsed hematologic malignancies <p>ABT-263 (RG7433)</p> <ul style="list-style-type: none"> Relapsed chronic lymphocytic leukaemia <p>Anti-IGF-1R (RG1507)</p> <ul style="list-style-type: none"> Advanced breast cancer Metastatic NSCLC Recurrent or refractory sarcoma <p>Avastin</p> <ul style="list-style-type: none"> 1L metastatic melanoma Extensive small cell lung cancer Relapsed multiple myeloma <p>BRAF Inh/PLX4032 (RG7204)</p> <ul style="list-style-type: none"> Metastatic melanoma <p>DR5 Agonist MAb (RG7425)</p> <ul style="list-style-type: none"> 1L metastatic NSCLC <p>Dulanermin (RG3639)</p> <ul style="list-style-type: none"> 1L metastatic NSCLC Indolent relapsed NHL <p>Hedgehog Pathway Inh/GDC-0449 (RG3616)</p> <ul style="list-style-type: none"> Advanced basal cell carcinoma 1L metastatic colorectal cancer Ovarian cancer maintenance therapy <p>Linifanib/ABT-869 (RG3635)</p> <ul style="list-style-type: none"> 1L metastatic breast cancer 1L metastatic NSCLC 2L metastatic colorectal cancer <p>MetMAb (RG3638)</p> <ul style="list-style-type: none"> 2L and 3L metastatic NSCLC <p>Pertuzumab</p> <ul style="list-style-type: none"> Neoadjuvant HER2+ breast cancer 2L metastatic NSCLC Platinum-resistant ovarian cancer³ <p>T-DM1 (RG3502)</p> <ul style="list-style-type: none"> 1L HER2+ metastatic breast cancer 3L HER2+ metastatic breast cancer <p>T-DM1 (RG3502) + pertuzumab (RG1273)</p> <ul style="list-style-type: none"> HER2+ metastatic breast cancer 	<p>INFLAMMATION (4 NMEs)</p> <p>Lebrizumab/Anti-IL13 (RG3637)</p> <ul style="list-style-type: none"> Asthma <p>Palovarotene (RG667)</p> <ul style="list-style-type: none"> Emphysema <p>Rontalizumab/Anti-IFNα (RG7415)</p> <ul style="list-style-type: none"> Systemic lupus erythematosus <p>S1P₁ Receptor Agonist (RG3477)</p> <ul style="list-style-type: none"> Plaque psoriasis <p>Xolair</p> <ul style="list-style-type: none"> Chronic idiopathic urticaria <p>VIROLOGY (3 NMEs)</p> <p>HPV16 (RG3484)</p> <ul style="list-style-type: none"> Cervical neoplasia <p>Nucleoside Analogue Polymerase Inh (RG7128)</p> <ul style="list-style-type: none"> Chronic hepatitis C <p>Protease Inh (RG7227)</p> <ul style="list-style-type: none"> Chronic hepatitis C <p>METABOLIC (2 NMEs)</p> <p>Aleglitazar (RG1439)</p> <ul style="list-style-type: none"> Type II diabetes <p>SGLT2 Inhibitor (RG7201)</p> <ul style="list-style-type: none"> Type II diabetes <p>CNS (2 NMEs)</p> <p>GLYT-1 Inh (RG1678)</p> <ul style="list-style-type: none"> Schizophrenia <p>Nicotinic α7 Agonist (RG3487)</p> <ul style="list-style-type: none"> Alzheimer's disease <p>Ocrelizumab (RG1594)</p> <ul style="list-style-type: none"> Relapsing remitting multiple sclerosis <p>S1P₁ Receptor Agonist (RG3477)</p> <ul style="list-style-type: none"> Multiple sclerosis <p>OTHER (1 NME)</p> <p>Motilin Agonist/GM-611⁴</p> <ul style="list-style-type: none"> Diabetic gastroparesis Irritable bowel syndrome 	

As of 15 October 2009

¹ Opt-in opportunity from Chugai; ² Opt-in opportunity from Biotie; ³ Phase III program under consideration; ⁴ Participation through Chugai; NME = New Molecular Entity.



Roche Group Late-stage Development Pipeline

PHASE III (6 NMEs)

ONCOLOGY (2 NMEs)

Avastin

- Adjuvant colon cancer
- Adjuvant HER2- breast cancer
- Adjuvant HER2+ breast cancer
- Adjuvant non-small cell lung cancer
- Diffuse large B-cell lymphoma
- First-line advanced gastric cancer
- First-line HER2- metastatic breast cancer
- First-line HER2+ metastatic breast cancer
- First-line metastatic ovarian cancer
- High risk carcinoma
- Hormone refractory prostate cancer
- Newly diagnosed glioblastoma multiforme
- Relapsed platinum-sensitive ovarian cancer
- Second-line HER2- metastatic breast cancer
- Second-line metastatic colorectal cancer

Avastin +/- Tarceva

- First-line maintenance advanced non-small cell lung cancer

Herceptin

- Adjuvant HER2+ breast cancer (HERA 2-year)
- Subcutaneous formulation in HER2+ breast cancer¹

MabThera/Rituxan

- Follicular non-Hodgkin's lymphoma maintenance

Pertuzumab (RG1273)

- First-line HER2+ metastatic breast cancer

Tarceva

- Adjuvant non-small cell lung cancer
- First-line metastatic EGFR mutant+ non-small cell lung cancer

Trastuzumab-DM1 (RG3502)

- Second-line HER2+ metastatic breast cancer

Xeloda

- Adjuvant breast cancer
- Adjuvant colon cancer

INFLAMMATION (2 NMEs)

RoActemra/Actemra

- Systemic juvenile idiopathic arthritis (sJIA)

MabThera/Rituxan

- ANCA-associated vasculitis

Ocrelizumab (RG1594)

- Lupus nephritis
- Rheumatoid arthritis

Eldecalcitol/ED-71²

- Osteoporosis

Xolair

- Asthma

METABOLIC (2 NMEs)

Dalcetrapib (RG1658)

- Dyslipidemia (high cardiovascular risk)

Taspoglutide (RG1583)

- Type II diabetes

OTHERS

EPOCH²

- Chemo induced anaemia

TNKase

- Central venous catheter clearance
- Hemodialysis catheter clearance

OPHTHALMOLOGY

Lucentis

- Diabetic macular edema
- Retinal vein occlusion
- High-dose in age-related macular degeneration

As of 15 October 2009

¹ Preparing to initiate clinical trial; ² Participation through Chugai; NME = New Molecular Entity.